Beike Biotech
  • Home
  • Beike History
  • Research & Development
    • Technology
    • Pipeline
  • Quality
  • Partnerships
  • News & Updates
  • Contact

Technologies

  1. Research
  2. Technologies
    1. MAR
    2. TriTE
    3. MAR-T

Research

Beike has published ground-breaking research in the adult stem cell field for over 10 years, utilizing umbilical cord blood and tissue as a source of stem cells.

Beike’s Two Types of Stem Cells

Beike provides and researches stem cells from two sources: umbilical cord blood and umbilical cord tissue. For some treatments, the research protocols may include the use of more than one type of stem cell.

Umbilical Cord Blood-Derived Stem Cells (UCBSC)

For many conditions, such as spinal muscular atrophy, ataxia, and optic nerve conditions, Beike has developed novel treatments using umbilical cord blood (UCB) stem cells. Our UCB stem cell injections consist of three subsets of stem cells: hematopoietic stem cells, endothelial progenitor cells, and mesenchymal stem cells. Hematopoietic stem cells and endothelial progenitor stem cells have been shown to develop into functional tissues. Mesenchymal stem cells can assist in the growth of chondrocytes – a type of cell critical to tissue renewal, particularly cartilage – as well as liver cells, kidney cells and neurons. In addition, such cells also possess the ability to aid in the repair of a variety of vascular disorders within the brain, eye, and throughout the body including the heart, kidney, and pancreas. From our findings to date, it is believed that the benefits patients report following treatment arise from the cell growth factors that are released by stem cells following administration.

Umbilical Cord-Derived Mesenchymal Stem Cells (UCMSC)

Based upon recent research and experience, Beike protocols utilize UCMSC for the treatment of conditions amenable to stem cell therapy. Our injections contain a higher percentage of mesenchymal stem cells than UCB stem cell injections and closely resemble the composition of cells cultured from bone marrow. As per our currently clinical guidelines, we recommend multiple sclerosis (MS) and spinal cord injury (SCI) patients receive this type of stem cell injection. Previously published studies have demonstrated UCMSC produce important chemicals, known as growth factors, and have the ability to differentiate into desired cell types, as well possessing the property of modulating the immune system, reducing inflammation, scarring, and reducing cellular apoptosis.

Below you can see Beike’s published research papers, as well as clinical translation case studies for stem cell treatments of a plethora of medical conditions. The papers are listed alphabetically.

Beike Research
Early Immunotherapy using Autologous Adult Stem Cells with Type 1 Diabetes Mellitus
Human CBMNC for Viral Encephalitis Associated Cognitive Impairment
Human UCBDMC Cell Transplantation Case of 30 Patients with Hereditary Ataxia
SLE-UC-MSC Transplantation in Severe and Refractory SLE
Therapeutic Effects of Human UCMSCs Against Acute Tubular Necrosis Quantified
Transplantation of Human CBMNCs and UCMSCs in Autism
Beike Case Studies
Amyotrophic Lateral Sclerosis American Male 51
Ataxia American Male 41
Ataxia - Descriptive Statistical Report on Ataxia Cases with Cell Therapy
Ataxia-Transplantation of Human UCBSC and Rehab for Ataxia
Autism Swedish Male 10
Brain Injury Brazilian Female 38
Brain Injury (Drowning) South African Female 5
Cerebral Palsy Argentinean Male 6
Cerebral Palsy-Beike Biotech Stem Cell Treatment for CP
Cerebral Palsy Brazilian Female 7
Cerebral Palsy Descriptive Statistical Report in CP cases with Stem Cell Therapy
Cerebral Palsy-Retinopathy of Prematurity American Male 13
Freidreich's Ataxia Argentinean Female 14
Glaucoma South African Female 39
Hearing Loss American Female 19
Hearing Loss American Male 4
Hearing Loss American Male 19
Hereditary Ataxia-HUCBD Mononuclear Cell Transplantation in 30 Subjects
Huntington's Disease Oman Female 33
Leber's Australian Male 11
Liver Cirrhosis-A Clinical Summary Of Stem Cell Therapy for Liver Cirrhosis
Liver Cirrhosis Polish Male 56
Macular Degeneration Canadian Male 58
Muscular Dystrophy American Male 12
Multiple Sclerosis Australian Female 30
Multiple Sclerosis Beike Biotech Stem Cell Treatment for MS
Multiple Sclerosis Descriptive Statistical report on MS Cases with Cell Therapy
Multiple Sclerosis Panamanian Female 46
Olivopontocerebellar Atrophy American Male 58
Optic Nerve Atrophy Irish Female 24
Optic Nerve Hypoplasia and Cerebral Palsy American Male 8
Optic Nerve Hypoplasia and Septo-optic Dysplasia Cases with Cell Therapy
Optic Nerve Hypoplasia Irish Female 16
Optic Neuropathy French Male 65
Retinitis Pigmentosa German Male 29
Retinitis Pigmentosa Taiwanese Male 35
Safety Evaluation of Umbilical Cord Blood Cell Therapy
Spinal Cord Injury American Female 41
Spinal Cord Injury American Male 24
Spinal Cord Injury American Male 53
Spinal Cord Injury Information Sheet
Spinal Muscular Atrophy 1 Hungarian Male 3
Spinal Muscular Atrophy 3 Indonesian Female 30
Septo-optic Dysplasia American Female 2
Septo-optic Dysplasia Cases with Cell Therapy
Spina Bifida American Male 2
Spina Bifida Serbian Male 13
Beike Medical Press
China Will Be the World Leader in Stem Cell Research
Groundbreaking Stem Cell Treatment Key to Cairn's Boy's Transformation
Memorable Week for Cora Beth Taylor
Stem Cell Tourism
Stem Cell Treatments Change Girl's Life
Stem Cells Help Man Cure HIV

Technologies

MAR

MAR (Major Histocompatibility Antigen Receptor) is a class of fully human single domain antibodies that bind MHC antigen complex and is a “T-cell receptor (TCR)-like antibody”. Binding to MHC antigen complexes enables MAR to be directed against intracellular targets, opening up novel possibilities to cancer immunotherapies.

For more information on MAR please visit http://timmune.com, our subsidiary for these technologies.

TriTE

TriTE (Tri-functional T cell Engager) is a fusion protein platform with a unique combination of antigen binding domains, a Sushi domain IL-15 binding pair and PD1. It provides an improved microenvironment for cancer immunotherapy.

For more information on TriTE please visit http://timmune.com, our subsidiary for these technologies.

MAR-T

MAR-T is a variant of CAR-T for adoptive T cell cancer therapy. It utilizes part of our proprietary TriTE platform and MAR and results in T cells with improved micro-environment functions and a higher number of binding targets with better binding specificity and affinity. This increases its potential for cancer immunotherapies over the traditional CAR-T.

For more information on MAR-T please visit http://timmune.com, our subsidiary for these technologies.

Connect With Us

facebook  youtube  twitter   vimeo  linkedin  google-plus

Menu

  • Home
  • Technologies
  • Pipeline
  • Quality
  • Partnership
  • News & Updates
  • Contact

Our Partners

  • Beike Cell Therapy
  • Better Being Hospital

© 2021 Beike Biotechnology Co., Ltd.
All rights reserved.